Natixis Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Natixis Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-959	Closed	-$371K	–	1513
2022 Q4	$371K	Buy	959 +6	+0.6%	+$2.28K	﹤0.01%	1360
2022 Q3	$321K	Buy	953 +34	+4%	+$12.3K	﹤0.01%	1370
2022 Q2	$302K	Sell	919 -136	-13%	-$47.7K	﹤0.01%	1376
2022 Q1	$461K	Buy	1,055 +531	+101%	+$218K	﹤0.01%	1301
2021 Q4	$230K	Buy	524 +8	+2%	+$4.02K	﹤0.01%	1345
2021 Q3	$287K	Sell	516 -115	-18%	-$57.7K	﹤0.01%	1274
2021 Q2	$324K	Buy	631 +214	+51%	+$136K	﹤0.01%	1272
2021 Q1	$326K	Sell	417 -2	-0.5%	-$1.37K	﹤0.01%	1223
2020 Q4	$228K	Buy	+419	New	+$220K	﹤0.01%	1199

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Natixis Advisors's TVRD Position: Q1 2023 in Review

Natixis Advisors sold out of Tvardi Therapeutics (TVRD) in Q1 2023, closing a stake of 959 shares — an estimated $371K sold.

Natixis Advisors first reported a position in TVRD in Q4 2020 and held it in 9 quarters. The position peaked at $461K in Q1 2022. 163 funds tracked by Wall St. Rank hold TVRD as of Q1 2023.

Natixis Advisors reported no remaining Tvardi Therapeutics position as of Q1 2023 after selling out during the quarter.
Natixis Advisors sold 959 Tvardi Therapeutics shares in Q1 2023, an estimated $371K.
Natixis Advisors first reported a position in Tvardi Therapeutics in Q4 2020 and held it in 9 quarters.
Natixis Advisors's Tvardi Therapeutics position peaked at $461K in Q1 2022.
163 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2023.

Based on Natixis Advisors's 13F filing for Q1 2023, filed 11 May 2023.